Saturday, March 8, 2025
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Positive Results from the Pivotal ADEPT Phase 2/3 trial
Regeneron Pharmaceuticals, Inc. and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.